Gunnar Olof Olsson
Chief Executive Officer chez IRLAB THERAPEUTICS AB
Fortune : 5 836 $ au 31/03/2024
Profil
Gunnar Olof Olsson is currently the Chief Executive Officer & Director at IRLAB Therapeutics AB.
He is also the Chairman at Athera Biotechnologies AB, Betagenon Sweden AB, Betagenon Bio AB, BioCrine AB, Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt, Gesynta Pharma AB, Olsson Solutions AB, Amplifier TX AB, and Cereno Scientific AB.
In the past, Dr. Olsson worked as a Director at The European Society of Cardiology and as a Manager-Global Cardiovascular at AstraZeneca AB.
He holds a doctorate degree from Karolinska Institutet and an undergraduate degree from the International Institute for Management Development.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 4 000 ( 0,01% ) | 5 836 $ | 31/03/2024 |
Postes actifs de Gunnar Olof Olsson
| Sociétés | Poste | Début |
|---|---|---|
| CERENO SCIENTIFIC AB | Director/Board Member | - |
| IRLAB THERAPEUTICS AB | Chief Executive Officer | 20/02/2023 |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Chairman | - |
| BioCrine AB | Director/Board Member | - |
Gesynta Pharma AB
 Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Director/Board Member | - |
| Olsson Solutions AB | Director/Board Member | - |
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt
 Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt Miscellaneous Commercial ServicesCommercial Services Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt is a non-profit organization based in Stockholm, Sweden. and has subsidiaries in Sweden. The organization's main objective is to raise funds for selected Swedish heart and lung research to help people live longer and healthier lives. The Swedish company works together with individuals and companies to collect and distribute funds for heart and lung research. The organization's vision is to create a world free from heart and lung disease. Kärlkramp, which is a temporary reduction of blood flow in the heart's coronary vessels and the main symptom is a squeezing chest pain, is one of the diseases they focus on. | Director/Board Member | - |
Betagenon Sweden AB
 Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | Chairman | 27/05/2021 |
| Betagenon Bio AB | Chairman | - |
| ░░░░░░░░░ ░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Gunnar Olof Olsson
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░ ░░░░░░░░ ░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Gunnar Olof Olsson
| Karolinska Institutet | Doctorate Degree |
| International Institute for Management Development | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CERENO SCIENTIFIC AB | Health Technology |
| IRLAB THERAPEUTICS AB | Health Technology |
| Entreprise privées | 10 |
|---|---|
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| BioCrine AB | |
| The European Society of Cardiology | |
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt Miscellaneous Commercial ServicesCommercial Services Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt is a non-profit organization based in Stockholm, Sweden. and has subsidiaries in Sweden. The organization's main objective is to raise funds for selected Swedish heart and lung research to help people live longer and healthier lives. The Swedish company works together with individuals and companies to collect and distribute funds for heart and lung research. The organization's vision is to create a world free from heart and lung disease. Kärlkramp, which is a temporary reduction of blood flow in the heart's coronary vessels and the main symptom is a squeezing chest pain, is one of the diseases they focus on. | Commercial Services |
Betagenon Sweden AB
Betagenon Sweden AB Pharmaceuticals: MajorHealth Technology Betagenon AB engages in development of AMP-activated protein kinase (AMPK) activator compounds chronic energy balance disorders diseases. The company was founded by Helena Edlund, Thomas Edlund and Olof Karlsson and is headquartered in Umea, Sweden. | Health Technology |
Gesynta Pharma AB
Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Health Technology |
| Olsson Solutions AB | |
| Betagenon Bio AB | |
Amplifier TX AB
 Amplifier TX AB BiotechnologyHealth Technology Part of Cambrian BioPharma, Inc., Amplifier TX AB is a Swedish biopharmaceutical company that develops clinical molecule AMPK activators. The private company is based in Umeå, Sweden. The company was founded in 2023 by Thomas Edlund, Helena Edlund. James Hall has been the CEO of the company since 2023. | Health Technology |
